IL17RC

Overview

IL17RC (Interleukin 17 Receptor C) encodes a subunit of the IL-17 receptor complex involved in inflammatory signaling. In the cancer immunotherapy context, IL17RC was identified among a pre-therapy gene expression signature associated with response to anti-PD-1 therapy in melanoma, nominated as an immune-environment modulator.

Alterations observed in the corpus

  • Highly expressed pre-therapy in CR/PR vs PD patients in the 189-DEG responder signature (q < 0.20) in advanced melanoma patients treated with nivolumab (CA209-038 trial, n=68); nominated as an immune-environment modulator. PMID:29033130

Cancer types (linked)

Co-occurrence and mutual exclusivity

  • Co-expressed with FGFR3 and IL17RE in the pre-therapy 189-DEG responder set, suggesting shared immune-regulatory context. PMID:29033130

Therapeutic relevance

  • No direct targeted therapy against IL17RC is reported in this corpus. High pre-therapy expression may serve as a predictive biomarker for anti-PD-1 response in melanoma, pending validation. PMID:29033130

Open questions

  • The 189-DEG analysis was limited by small sample size (n~13 CR/PR vs ~19 PD); IL17RC as a standalone predictive biomarker requires prospective validation.
  • The mechanistic basis for IL17RC expression predicting anti-PD-1 response in melanoma is not established. PMID:29033130

Sources

This page was processed by crosslinker on 2026-05-15.